<abstract>
<title style='display:none'>Abstract</title>
Any chosen analytical method should be subtle, precise, fast and exact to begin the guarantee that the material used in the manufacturing is free of unsolicited impurity, the existence of which may vary the safety and effectiveness of the drug product. The techniques of HPLC and UPLC have established their part in pharmaceutical cleaning validation. High-Performance Liquid Chromatography (HPLC) is the main pharmaceutical and biomedical analysis approach utilized today because it generates highly efficient separations, and in most circumstances, it provides high detection sensitivity. Applying the HPLC method has several advantages compared to other methods, among others, specificity, rapidity, accuracy, precision, and the ease of automation. Due to the aforementioned, most drugs in a multi-component dosage form can be analyzed. Ultra-Performance Liquid Chromatography (UPLC) is a modern-day technique that gives a new track for liquid chromatography. UPLC provides the user with speed of application, resolution and sensitivity. The quantification and separation in UPLC are done under very high pressure (up to 100M Pa). High-Performance Thin Layer Chromatography (HPTLC) has improved and innovative separation efficacy and detection limits. It is a cultured and automated form of Thin Layer Chromatography (TLC) and is based on the use of an optimized silica gel 60 with a significantly smaller particle size than which is used for TLC. The previously stated analytical methods are employed for purity control of chemicals, steroids, pesticides, and water analysis, water-soluble food dyes, vitamins, pesticides in vegetables, fruits, and other foodstuffs. The current updates in the techniques allow us to understand the increased utilization of these methods in the current eras.
</abstract>

A comparative review on High-Performance Liquid Chromatography (HPLC), Ultra Performance Liquid Chromatography (UPLC) &amp; High-Performance Thin Layer Chromatography (HPTLC) with current updates

<abstract><title style='display:none'>Abstract</title> Fever develops in various diseases. It is mainly associated with infectious diseases but can also occur in non-infectious ailments. Clinical symptoms are not always explicit, which can hinder the diagnosis and delay the institution of appropriate treatment. The aim of the study is to present difficulties in diagnosing the cause of a febrile state in a patient with splenic abscess.</abstract>

Different faces of a febrile state

<abstract><title style='display:none'>Abstract</title>Histamine type 2 receptor antagonists are one of the most commonly used agents to treat peptic ulcer disease. Since patients with epilepsy may have many comorbidities, the aim of this study was to investigate the influence of one of the strongest second generation histamine type 2 receptor antagonist, famotidine, on the exploratory and spontaneous activity in mice after 1 or 7 days treatment. Additionally, the interaction between famotidine and antiepileptics: carbamazepine, phenytoin, phenobarbital or valproate and their effect on animals activity was also evaluated. Locomotor activity was monitored electronically using a Digiscan analyzer in relation to ambulatory and rearing activities, as well as total distance travelled by animals during 15 minute periods. Results of our study indicate that famotidine administered alone did not modulate three variables of exploratory motor activity (horizontal activity, total distance and vertical activity) in mice. On the other hand, famotidine co-administered with valproate (1 day) or phenobarbital (1 day or 7 days) worsened vertical activity in mice in exploratory time. Similarly, impairment in horizontal activity in mice was observed when famotidine was given with phenobarbital (1 or 7 days). An increase in total distance in mice after famotidine alone or in combination with tested antiepileptic drugs was also shown. Moreover, famotidine alone or together with antiepileptic agents significantly impaired spontaneous locomotor activity in mice. The presented results show that famotidine administration to patients with epilepsy should be considered as potentially hazardous.</abstract>

Effect of famotidine in combination with antiepileptic drugs on locomotor activity in mice

<abstract><title style='display:none'>Abstract</title> A rapid, simple and sensitive capillary zone electrophoresis method was developed for the simultaneous determination of amlodipine besylate and telmisartan, in fixed-dose combinations, through the utilization of a UV photodiode array detector. Electrophoretic parameters such as buffer concentration and pH, system temperature, applied voltage and injection parameters, were optimized in order to improve the efficiency of the separation. The best results were obtained when employing fused silica capillary (48 cm length X 50 μm ID) and 50 mM phosphate buffer electrolyte at pH 4.50, + 25 kV applied voltage, as well as 25°C system temperature. The separation was achieved in approximately 3 minutes, with a resolution of 4.90, while the order of migration was amlodipine followed by telmisartan. The analytical performance of the method was verified with regard to linearity, precision and robustness. In addition, the limit of detection and the quantification were calculated.</abstract>

Simultaneous determination of amlodipine and telmisartan from pharmaceutical products by way of capillary electrophoresis

<abstract><title style='display:none'>Abstract</title> In this study, the stability of 10% hydrogen peroxide aqueous and non-aqueous solutions with the addition of 6% (w/w) of urea was evaluated. The solutions were stored at 20°C, 30°C and 40°C, and the decomposition of hydrogen peroxide proceeded according to first-order kinetics. With the addition of the urea in the solutions, the decomposition rate constant increased and the activation energy decreased. The temperature of storage also affected the decomposition of substance, however, 10% hydrogen peroxide solutions prepared in PEG-300, and stabilized with the addition of 6% (w/w) of urea had the best constancy. </abstract>

Chair and Department of Applied Pharmacy, Faculty of Pharmacy, Medical University of Lublin, 1 Chodzki, 20-093 Lublin, Poland

Chair and Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Unit., Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, 4a Chodzki, 20-093 Lublin, Poland

Kinetics of the decomposition and the estimation of the stability of 10% aqueous and non-aqueous hydrogen peroxide solutions

<abstract><title style='display:none'>Abstract</title> The marginal bone loss around dental implants is an important indicator that helps to evaluate the course and the final outcome of implant-prosthetic treatment. It is, therefore, important to understand the factors that may affect this. The aim of the study was to assess the impact of the specific characteristics of implant-prosthetic treatment on the marginal bone loss around implants. The study included 28 patients, aged 37-66 years, treated with dental implants. Every patient received at least one of the two types of implants: with Morse taper connection and with internal hexagonal connection. The average marginal bone loss around the implants was evaluated on the basis of the panoramic radiographs. The maximum follow-up period after implantation was 46 months. The peri-implant marginal bone loss was evaluated taking into consideration the implant localisation, the procedure of sinus lift with bone augmentation, implant type, implant diameter, vertical implant position relative to the compact bone level and the type of prosthetic restoration, the time between implantation and loading with prosthetic restoration, as well as the time between loading and the measurement of marginal bone loss. The correlation between bone loss and the selected characteristics of the treatment was assessed using generalised estimating equations (GEE). An objective analysis was enabled via the applied research model: evaluation of an impact of the specific implant-prosthetic treatment characteristics on peri-implant marginal bone loss in patients treated with implants with different implant-abutment interface systems. The results of the study showed that peri-implant marginal bone loss increased significantly with implant localisation in canine sites (compared to the localization in premolar sites), as well as with prosthetic restorations in the form of dentures (compared to bridges), and decreased when implants were placed below the compact bone level (compared to those placed at the bone level). At the same time, marginal bone loss was not significantly related to implant diameter or to the sinus lift procedure. The results obtained seem extremely useful in everyday clinical practice</abstract>

The Relationship Between Marginal Bone Loss Around Dental Implants and the Specific Characteristics of Implant-Prosthetic Treatment

<abstract><title style='display:none'>Abstract</title>
Different levels of miR-625-5p, miR-31-5p and miR-5100 have been reported in many cancers. Viral infections have been linked to miRNA levels in tumors, including those in the head and neck, but a large proportion of studies only include infections with a single virus. The aim of the present study is to assess the level of miR-625-5p, 31-5p and 5100 in oropharyngeal cancer with single HPV and EBV infections and HPV/EBV co-infection. The study examined 128 oropharyngeal cancer patients infected with EBV and HPV alone or co-infected with both viruses. For the determination of miRNAs, the enzyme immunoassays was used. Both miR-625-5p and miR-31-5p were higher in the HPV/EBV co-infection than in the single infection HPV or EBV. However, in the case of miR-5100, the values in co-infection were lower than in a single EBV infection. The analysis of miRNAs in relation to the histological grade and tumor classification, nodes (TN) showed that in poorly differentiated tumors the level of the studied miRNAs was higher compared to well-differentiated lesions, and in cases with larger tumor sizes and lymph node involvement, the miRNA values were both higher in single infections and co-infections.
</abstract>

Selected miRNAs in oropharyngeal squamous cell carcinoma (OPSCC) with HPV and EBV coinfection

<abstract><title style='display:none'>Abstract</title>
The Pharmaceutical Law Act of September 6, 2001 (PLA) initially granted pharmacists the authority to issue pharmaceutical prescriptions upon its enactment. However, the legislation regulating this matter changed significantly in 2015. Article 96, section 4 of the PLA defined that, in the front of a direct health threat to a patient, a pharmacist could dispense a medication classified under the availability categories Rp or Rpz. In April 2020, the imprecise term “sudden” in relation to health threats was clarified and removed. Concurrently, all active pharmacists were granted the authority to issue prescriptions, commonly known as <italic>pro auctore</italic> and <italic>pro familiae</italic>. The aim of the study was to illustrate the influence of legislative processes on the number of prescriptions issued by practicing pharmacists. To conduct the study, we employed a legal and comparative analysis of relevant legal provisions, followed by a statistical analysis of data obtained from the E-Health Center about the number of prescriptions issued. The results indicated that since the extension of pharmacists’ rights (after April 2020), the average number of pharmaceutical prescriptions issued per month was 151,082. Between May 2020, when pharmacists were granted the authority to issue <italic>pro auctore</italic> and <italic>pro familiae</italic> prescriptions, and October 2023, 1,460,385 such prescriptions were dispensed. As a result, a significant relationship between the form of the legislative norms empowering pharmacists to independently prescribe Rx status medicines and the effectiveness of these amendments as measured by the number of prescriptions issued was demonstrated.
</abstract>

Changes in pharmaceutical prescription authorizations and their impact on the number of prescriptions issued by pharmacists in Poland

<abstract><title style='display:none'>Abstract</title>
The safety and efficacy of multivitamin-multimineral-multiherbal (MVMH) supplementation is in regular debate but should be studied in detail before recommendation. The purpose of the study was to evaluate whether MVMH supplementation affects the physical and mental performance of individuals taking these, as well as to ascertain its safety, doing so through blood, kidney and liver profiles.
In this Cross over cohort study, we enrolled 30 healthy volunteers and established their anthropometric, stress, anxiety and depression levels before and after 30 days of the study. Their kidney function test, liver function test and blood profile results were also analysed to determine overall health effects of the supplement and assess its safety. Parametric data was examined via Paired T test, followed by One Way ANOVA, Non-parametric data is presented as percentage and analysed by applying Paired Sample Wilcoxon Signal Rank Test followed by Friedman ANOVA test.
All the volunteers were in good health, had no change in medical state. No serious adverse event was reported during the study and after the completion of study. Treatment with MVMH tablets had shown very significant (p &lt;0.01) increase in the level of globulin, uric acid (p &lt;0.05), hemoglobin, and hematocrit levels (p &lt;0.05), BMI and body weight (p &lt;0.05). There was significant (p &lt;0.05) improvement in symptoms of anxiety, depression and stress.
The daily intake of MVMH supplements in the form of a tablet once per day improved global health of individuals, along with improvement in mental performance without any significant adverse impact on the body. Based on the results, we recommend that MVMH tablets may be taken once per day for 30 days to improve the physical and mental health of individuals.
</abstract>

Impact of dietary and herbal supplements on global health of adult volunteers

<abstract><title style='display:none'>Abstract</title>
Clinical trials are an integral part of the process of developing new drugs, diagnostic methods and medical devices. Clinical trials offer patients the chance to access alternative treatment methods, thereby improving their quality of life, and even achieving recovery. Additionally, clinical trials provide the opportunity for regular contact with a specialist doctor and easier access to diagnostics, ensuring a faster therapeutic path for the patient. One of the key aspects of conducting clinical trials is choosing the right investigator and research center so as to meet specific criteria and guarantee high quality of the conducted studies. Therefore, the aim of the current study was to evaluate the differences between conducting clinical trials in public and commercial centers. A diagnostic survey was used in the study and the research tool chosen was a proprietary questionnaire belonging to the research technique as survey questionnaire. Questionnaires were constructed for the appropriate stakeholders/respondents, namely: doctors and employees of pharmaceutical companies and CROs. The analysis showed that employees of pharmaceutical companies, given the choice, prefer to cooperate with commercial centers. They choose public centers only when they need a center for phase one trials or those requiring hospitalization. The research obtained shows that public centers should improve administrative processes in order to optimize tasks such as contracting or obtaining a study.
</abstract>

A comparison of the potential of Clinical Trials Centers within both public and commercial trial facilities

<abstract><title style='display:none'>Abstract</title>
The review aimed to illustrate the structure, role and effects of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) in combination with acetylsalicylic acid (aspirin, ASA) in various clinical cases. This verification of earlier single studies may be a guide in the further treatment of civilization diseases. The results of the presented narrative review suggest that aspirin supplementation with omega-3 fatty acids reduces pro-inflammatory biomarkers in sepsis and acute respiratory distress syndrome. Including adequate amounts of omega 3-PUFAs in therapy, rather than increasing the dose of acetylsalicylic acid, may contribute to beneficial effects in treating thrombosis and preventing myocardial infarction or other cardiovascular diseases, which is particularly important in aspirin-resistant patients. As suggested in the literature, a low daily dose of omega-3 fatty acids was effective in slowing the progression of kidney disease with IgA nephropathy. Aspirin supplementation with omega-3 fatty acids has improved clinical and immunological outcomes in the treatment of periodontitis or the therapy of colorectal cancer tumor lesions. The synergistic effect of both compounds is proposed as a new therapeutic option in the treatment of Parkinson’s disease. Further research into the synergistic effects of omega-3 fatty acids in combination with acetylsalicylic acid may provide a breakthrough in drug dose reduction, ultimately enabling more effective and safer pharmacotherapy for the patient. Therefore, studies on polyunsaturated fatty acids in combination with nonsteroidal anti-inflammatory drugs <italic>in vivo</italic> are needed.
</abstract>

Synergistic effects of omega-3 polyunsaturated fatty acids and aspirin in the clinical practice – a narrative review

<abstract><title style='display:none'>Abstract</title>
Anemia is a grave public health issue that affects 25% of the global population. Conventional iron formulations used in treatment have drawbacks such as poor bioavailability and gastric intolerability. The current study aimed to evaluate the anti-anemic effects of different iron salts in Wistar rats with iron deficiency anemia (IDA). IDA was induced by the validated pre-clinical model by retro-orbital bloodletting (1 ml) for 21 days along with an iron-deficient diet in Wistar rats. The rats (n=48) were assigned into 8 groups: Control group, IDA rats, IDA rats receiving either vehicle or different iron salts (ferrous sulfate, ferrous ascorbate, ferrous fumarate, and Sucrosomial iron) for 21 days at a dose of 30 mg/kg p.o. Hematological parameters and iron store indices were assessed at each visit.
Anemia induction markedly reduced hemoglobin levels in all IDA groups on day 21. In contrast, iron supplements showed significant improvement in hematological profile after 21 days of treatment. Interestingly, the Sucrosomial iron-supplemented group (group 8) showed significantly higher improvement in hemoglobin levels and hematocrit than did conventional iron supplements such as ferrous sulfate (group 5), ferrous ascorbate (group 6) and ferrous fumarate (group 7) (p &lt;0.05 for each group, respectively). Sucrosomial iron also showed slightly better improvement in iron store indices (serum iron &amp; ferritin levels, total iron binding capacity and transferrin saturation [%]) when compared with other iron supplements (non-significant difference).
Authors concluded that Sucrosomial iron has a significant potential to improve IDA in Wistar rats compared to conventional iron salts. Sucrosomial iron can be useful for the management of IDA either prophylactically or therapeutically.
</abstract>

Comparative evaluation of anti-anemic effect of Sucrosomial iron in experimental model of iron deficiency anemia in Wistar rats

<abstract><title style='display:none'>Abstract</title> Over the past five years, phytochemical and pharmacological studies have been conducted on material extracted from members of the Rutaceae family. In such work, new furochinoline-structured alkaloids were isolated from Ruta sp. and Dictamnus sp. Beyond the aforementioned, other substances with promising activity were isolated from the less-known species of Zanthoxylum, Evodia, Lonchocarpus, Myrthopsis and Teclea. Currently used forms of extraction, as well as methods of isolation and detection, allow the obtaining of pure, biologically active compounds. Many of these have antifungal, anti-bacterial and anti-plasmodial properties. Others are still being researched as potential drugs, which, in future, may be used in treating those afflicted with HIV and cancer. This article is designed to give the readers a thorough review of the active natural products from the Rutaceae family.</abstract>

Hibiscus Pharmacy, 26 Puławska Str, 02-512 Warszawa, Poland

Department Pharmacognosy with Medical Plant Unit, Medical University of Lublin, 1 Chodzki , 20-093 Lublin, Poland

Furochinoline alkaloids in plants from Rutaceae family – a review

<abstract><title style='display:none'>Abstract</title>A simple, fast, and highly selective RP-HPLC method was developed for the determination of Dapagliflozin (DAP) and Saxagliptin (SAX) in API and tablet dosage form. The separation was done using a Xterra RP18 (4.6×150 mm, 5 μm particle size) column with Acetonitrile: water (60:40). The isocratic elution mode at a flow rate of 1 mL/min, and the analytes were measured at 248 nm. The retention time for DAP and SAX were about 2.091 and 3.249 min, respectively. Calibration curves were found to be linear in the ranges of 100-500 μg/ml for DAP and 50-250 μg/ml for SAX, with correlation coefficients of 0.9998. The detection and quantification values for DAP was 3.0 and 9.98 μg/ml and SAX was 3.02 and 10 μg/ml respectively.</abstract>

Stability indicating HPLC method for the simultaneous determination of dapagliflozin and saxagliptin in bulk and tablet dosage form

<abstract><title style='display:none'>Abstract</title>The present investigation was to estimate the total phenolic content and composition of flavonoids and hydroxycinnamic acids in herbal infusions obtained from aerial parts of three <italic>Lamiaceae</italic> species (<italic>Dracocephalum moldavica, Ocimum americanum</italic> and <italic>Satureja hortensis</italic>). The total phenolic content of herbal infusions was determined using a spectrophotometric method, whereas the individual phenolics were assessed by high-performance liquid chromatography (HPLC). The HPLC method was developed and validated. The total phenolic content was measured by applying the Folin-Ciocalteu method with reference to gallic acid. Results were in the range from 29.39 to 65.38 mg estimated as gallic acid equivalents per gram of dry herb. The phenolic profile was, in turn, analysed by HPLC and consisted of gallic acid, hydroxycinnamic acids (caffeic, chlorogenic, ferulic, and rosmarinic) and flavonoids (rutin, hyperoside, quercitrin, quercetin, apigenin, apigenin-7-glucoside and catechin) in different concentrations. Rosmarinic acid was the predominant component among the hydroxycinnamic acids in herbal infusions of all three plants. This was found to be in the range of 3.64 to 5.28 mg per gram of dry herb. Apigenin-7-glucoside, quercitrin and hyperoside were the prevailing flavonoid components of the infusions.</abstract>

Phenolic compounds of herbal infusions obtained from some species of the <italic>Lamiaceae</italic> family

<abstract><title style='display:none'>Abstract</title> Adipose tissue is at a point of high interest in medical research, not only as an energy depot, but also because it secretes nearly more than 600 cytokines. These are termed‚ adipokines’. Human adipokines are involved in numerous metabolic processes, including the regulation of appetite, energy expenditure, insulin sensitivity, inflammation and cardiovascular activity. Thus, these could be clinically important as a markers of adipose tissue function and increased metabolic risk. The search for novel adipokines linking obesity to related co-morbidities has become a major topic in obesity research. In such work, there is an increasing need to define their function, their molecular targets and their potential clinical relevance as biomarkers or in the treatment of obesity and other metabolic diseases. Omentin (34 kDa) is a recently identified fat deposition-specific adipokine with multiple interactions. Concentrations of omentin have been shown to be decreased in patients with obesity and impaired glucose regulation, in patients afflicted with diabetes type 1 and 2, and in patients with polycystic ovary syndrome. These are all diseases commonly associated with insulin resistance and obesity. The aim of this study was to show and compare the latest information about omentin and its relationships with obesity, diabetes mellitus (DM), metabolic syndrome (MetS), inflammation, cardiac problems, sex hormone imbalances and cancer. The association of omentin with particular metabolic indexes may suggest that an elevation in omentin level may be seen as being a marker for leanness, while a decreased level will underline possible situations of overweight and obesity along with their comorbidities (diabetes, cardiovascular disease, metabolic syndrome, inflammation and even cancer). However, a challenge for the future is to fully understand the multiple role played by omentin. Thus, more studies in these matter are required.</abstract>

Department of Laboratory Diagnostics, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

Chair and department of Human Physiology, Medical University of Lublin, Radziwillowska 11, 20-080 Lublin, Poland

Omentin - a new adipokine with many roles to play

<abstract><title style='display:none'>Abstract</title> Temporomandibular disorders (TMD) constitute a group of clinical problems involving the masticatory muscles, the temporomandibular joint and associated structures. An etiological connection of TMD with psychological factors was proposed as early as the 1980’s. Indeed, the interdependence of psychological and health aspects in the patient’s treatment, place light upon the more important variables contributing to the various mental disorders that may accompany TMD. Current literature suggests a close relationship between TMD and selected psychological factors, such as personality traits, stress, depression, anxiety, and catastrophizing. Of note, anxiety-depressive disorders, somatisation and catastrophizing contribute to chronic TMD, mainly in the form of myofascial pain. Hence, knowledge of the influence of psychological factors affecting TMD, enables the identification of patients with an increased risk of chronic painful TMD.</abstract>

Department of Functional Masticatory Disorders, Medical University of Lublin, Poland

Department of Dental Prosthetics, Medical University of Lublin, Poland

General Psychology Department, Institute of Psychology, Maria Curie-Sklodowska University, Lublin, Poland

Chair and Department of Paedodontics, Medical University of Lublin, Karmelicka 7, 20-081 Lublin, Poland

Psychological aspects of temporomandibular disorders – literature review

<abstract><title style='display:none'>Abstract</title>The paper is a report of the examination of the tribological wear characteristics of certain dental metal biomaterials. In the study, tests were undertaken on the following materials: 316L steel, NiCrMo alloy, technically pure titanium (ASTM-grade 2) and Ti6Al4V ELI alloy (ASTM-grade 5). The tribological tests were performed in artificial saliva to determine the coefficient of friction and wear factor; the traces of wear were then ascertained through SEM. The significance of variations in the wear factor, was subsequently assessed by the U Mann-Whitney test. The resistance to wear in the ball-on-disc test under in vitro conditions was observed for the tested materials in the following order: NiCrMo&gt;316L&gt;Ti6Al4V&gt;Ti grade 2.</abstract>

Tribological characteristics of dental metal biomaterials

Guidelines for Authors

Open Access License

Current Issues in Pharmacy and Medical Sciences

Formerly Annales UMCS Sectio DDD Pharmacia

 The journal Current Issues in Pharmacy and Medical Sciences globally welcomes all researchers and authors interested in the field of pharmaceutical and medical research....

Impact Factor

Five Year Impact Factor

Cite Score

SNIP

MNiSW

 The journal Current Issues in Pharmacy and Medical Sciences globally welcomes all researchers and authors interested in the field...

AHEAD OF PRINT

Volume 37 (2024): Issue 1 (March 2024)

Volume 36 (2023): Issue 4 (December 2023)

Volume 36 (2023): Issue 3 (September 2023)

Volume 36 (2023): Issue 2 (June 2023)

Volume 36 (2023): Issue 1 (March 2023)

Volume 35 (2022): Issue 4 (December 2022)

Volume 35 (2022): Issue 3 (September 2022)

Volume 35 (2022): Issue 2 (August 2022)

Volume 35 (2022): Issue 1 (July 2022)

Volume 34 (2021): Issue 4 (December 2021)

Volume 34 (2021): Issue 3 (September 2021)

Volume 34 (2021): Issue 2 (June 2021)

Volume 34 (2021): Issue 1 (March 2021)

Volume 33 (2020): Issue 4 (December 2020)

Volume 33 (2020): Issue 3 (September 2020)

Volume 33 (2020): Issue 2 (June 2020)

Volume 33 (2020): Issue 1 (March 2020)

Volume 32 (2019): Issue 4 (December 2019)

Volume 32 (2019): Issue 3 (September 2019)

Volume 32 (2019): Issue 2 (June 2019)

Volume 32 (2019): Issue 1 (March 2019)

Volume 31 (2018): Issue 4 (December 2018)

Volume 31 (2018): Issue 3 (September 2018)

Volume 31 (2018): Issue 2 (June 2018)

Volume 31 (2018): Issue 1 (March 2018)

Volume 30 (2017): Issue 4 (December 2017) 4th International Conference “Advances in Surgical Oncology”: Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy Lublin